Related references
Note: Only part of the references are listed.Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism A Randomized Trial
Benjamin Planquette et al.
CHEST (2022)
Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review
Florian Moik et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients-30 months follow-up
Trine-Lise Larsen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel
Jakob M. Riedl et al.
THROMBOSIS AND HAEMOSTASIS (2022)
Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs
Jordan K. Schaefer et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study)
Nils Picker et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Direct Oral Anticoagulant Versus Low Molecular Weight Heparin for the Treatment of CancerAssociated Thromboembolism: 2021 Updated Meta-Analysis of Randomized Controlled Trials
Corinne Frere et al.
BLOOD (2021)
Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study
Walter Ageno et al.
THROMBOSIS AND HAEMOSTASIS (2021)
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Gary H. Lyman et al.
BLOOD ADVANCES (2021)
Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
Brian J. Carney et al.
BLOOD ADVANCES (2021)
OC-15 Risk factors of recurrence in cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a RIETE-based prospective study
F.X. Lapébie et al.
THROMBOSIS RESEARCH (2021)
Executive Summary Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
Scott M. Stevens et al.
CHEST (2021)
The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial.
Deborah Schrag et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis
Lucia Caiano et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy
Tzu-Fei Wang et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Risk Assessment Models for Thrombosis and Anticoagulant-Related Bleeding in Ambulatory Cancer Patients
Matteo Candeloro et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2021)
Cancer-Associated ThrOmboSis - Patient-Reported OutcoMes With RivarOxaban (COSIMO) - Baseline characteristics and clinical outcomes
Anthony Maraveyas et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2021)
Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus
Marc Carrier et al.
CURRENT ONCOLOGY (2021)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
Nigel S. Key et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial
Robert D. McBane et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis
Lisette F. van Dam et al.
BLOOD (2020)
Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)
Andrea Marshall et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study
Florian Posch et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Prognosis in patients with cancer-associated venous thromboembolism: Comparison of the RIETE-VTE and modified Ottawa score
Nubio Pfaundler et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism
Robert A. Schmidt et al.
THROMBOSIS RESEARCH (2020)
l A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer
Alym Abdulla et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Long-Term Treatment of Cancer-Associated Thrombosis (CAT) Beyond 6 Months in the Medical Practice: USCAT, a 432-Patient Retrospective Non-Interventional Study
Isabelle Mahe et al.
CANCERS (2020)
Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review
Allen Li et al.
THROMBOSIS RESEARCH (2020)
Patients experience of living with cancer associated thrombosis in France (Le PELICAN)
Isabelle Mahe et al.
THROMBOSIS RESEARCH (2020)
Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases
Avi Leader et al.
BLOOD ADVANCES (2020)
Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials
Florian Moik et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study
Marcello Di Nisio et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Dominique Farge et al.
LANCET ONCOLOGY (2019)
Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors
B. J. Carney et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects
Wonkyung Byon et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH
B. T. Samuelson Bannow et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study
Noemie Kraaijpoel et al.
THROMBOSIS AND HAEMOSTASIS (2018)
D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis
Luis Jara-Palomares et al.
BRITISH JOURNAL OF CANCER (2018)
Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study
B. Tardy et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant
I. Elalamy et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study
Luis Jara-Palomares et al.
THROMBOSIS RESEARCH (2017)
Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis
Alok A. Khorana et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2017)
A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation
J. I. Zwicker et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Predictors of recurrent venous thromboembolism and bleeding on anticoagulation
Laurel A. Menapace et al.
THROMBOSIS RESEARCH (2016)
Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study
Jessica Donato et al.
BLOOD (2015)
Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology
Simon Noble et al.
HAEMATOLOGICA (2015)
Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule
Dolly A. Parasrampuria et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis
S. Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12months: the DALTECAN Study
C. W. Francis et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial
G. Agnelli et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology
Simon Noble et al.
HAEMATOLOGICA (2015)
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study
Cheng E. Chee et al.
BLOOD (2014)
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Sam Schulman et al.
CIRCULATION (2014)
Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study
Mariasanta Napolitano et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis
Ryma Ihaddadene et al.
THROMBOSIS RESEARCH (2014)
Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis
Marc Carrier et al.
THROMBOSIS RESEARCH (2014)
The effect of food on the absorption and pharmacokinetics of rivaroxaban
Jan Stampfuss et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism
Martha L. Louzada et al.
CIRCULATION (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients
M. Carrier et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Antithrombotic therapy for venous thromboembolic disease
Clive Kearon et al.
CHEST (2008)
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry
Davide Imberti et al.
HAEMATOLOGICA (2008)
American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
Gary H. Lyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period
Steven R. Deitcher et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2006)
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
AYY Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
P Prandoni et al.
BLOOD (2002)
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer - A randomized controlled study
G Meyer et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Share Paper
